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DCs  are  the  major  antigen-presenting  cell   
population involved in T cell priming. This is 
a complex group of cells that consists of several 
different subsets in the skin and lymphoid or-
gans, each of which may be specialized for their 
role in response to different types of cellular, 
microbial, and protein antigens.
Consistent with this hypothesis, two func-
tionally distinct subsets of classical DCs (cDCs) 
are present in the lymphoid organs of mice,   
including CD8+ and CD8 cDCs (Shortman 
and Liu, 2002). CD8+ cDCs are more potent at 
cross-presenting soluble and cell-associated anti-
gens to CD8+ T cells when compared with 
CD8CD11b+ cDCs (Heath et al., 2004). CD8+ 
cDCs preferentially prime CD8+ T cells, where-
  as CD8CD11b+ cDCs are more efficient in 
processing and presenting antigen to CD4+  
T cells (Dudziak et al., 2007).
The skin contains three DC compartments 
that consist of epidermal LCs and two pheno-
typically distinct cDC populations in the dermis   
(Bursch et al., 2007; Ginhoux et al., 2007; Poulin 
et al., 2007). These include the CD11c+CD11b+ 
cDC subset that is thought to be the main DC 
population in the dermis, as well as the recently 
identified CD103+langerin+CD11blocDC subset   
(Bursch et al., 2007; Ginhoux et al., 2007; Poulin   
et al., 2007; Nagao et al., 2009). CD103+ cDCs 
have also been identified in the lung (Sung   
et al., 2006) and in the intestine (Annacker et al., 
2005). Dermal CD103+ cDCs resemble CD8+ 
cDCs in lymphoid organs in that both of these   
subsets excel in cross-presentation of cell-associated   
antigens (Bedoui et al., 2009) and also that dele-
tion of the transcription factor Batf3 (basic leucine 
zipper transcription factor, ATF-like 3) elimi-
nates dermal CD103+ cDCs and lymphoid organ 
CD8+ cDCs, whereas other DC subsets in these 
tissues remain unaffected (Hildner et al., 2008). 
Thus, CD8+ cDCs in lymphoid organs and der-
mal CD103+ cDCs appear to be related. Whether 
similar DC subsets exist in all nonlymphoid tis-
sues and how they are related to cDCs and mac-
rophages remains unclear.
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CD103+ dendritic cells (DCs) in nonlymphoid tissues are specialized in the cross-presentation  
of cell-associated antigens. However, little is known about the mechanisms that regulate the 
development of these cells. We show that two populations of CD11c+MHCII+ cells separated on 
the basis of CD103 and CD11b expression coexist in most nonlymphoid tissues with the excep-
tion of the lamina propria. CD103+ DCs are related to lymphoid organ CD8+ DCs in that they are 
derived exclusively from pre-DCs under the control of fms-like tyrosine kinase 3 (Flt3) ligand, 
inhibitor of DNA protein 2 (Id2), and IFN regulatory protein 8 (IRF8). In contrast, lamina propria 
CD103+ DCs express CD11b and develop independently of Id2 and IRF8. The other population of  
CD11c+MHCII+ cells in tissues, which is CD103CD11b+, is heterogenous and depends on both 
Flt3 and MCSF-R. Our results reveal that nonlymphoid tissue CD103+ DCs and lymphoid organ 
CD8+ DCs derive from the same precursor and follow a related differentiation program.
© 2009 Ginhoux et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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plasmacytoid  DC  differentiation  potential  (Liu  et  al.,  2009).   
Pre-cDCs circulate through the blood to localize in lymphoid 
organs where they differentiate into both lymphoid organ cDC 
subsets, including CD8+ and CD8 cDCs (Liu et al., 2009).
Thus, monocytes and DC lineages separate in the BM at 
the MDP stage (Liu et al., 2009). The DC-restricted lineage 
does not give rise to monocytes and macrophages, and mono-
cytes are unable to give rise to lymphoid organ cDCs in the   
Recent studies have identified the discrete cellular steps that 
characterize DC lineage commitment in the BM. The macro-
phage and DC precursor (MDP; Fogg et al., 2006) gives rise to 
monocytes and to the common DC precursor (CDP; Liu et al., 
2009), which has lost monocyte/macrophage differential poten-
tial and gives rise exclusively to plasmacytoid DCs and lymphoid 
organ cDCs (Naik et al., 2007; Onai et al., 2007b). CDP also 
produces pre-cDC, a cDC-restricted progenitor that has lost 
Figure 1.  Two major phenotypically distinct DC subsets coexist in the dermis, lung, liver, pancreatic islets, and kidney. (A and B) Dermal cell sus-
pensions isolated from langerin/EGFP, CX3CR1/EGFP, and WT C57BL/6 mice were analyzed by flow cytometry. (A) Dot plot shows the expression of langerin 
and CD11b on gated DAPICD45+CD11c+I-A+ dermal DCs, allowing the discrimination of three DC subsets. (B) Histograms show the expression levels of 
CD103, EpCAM, CX3CR1, SIRP-, and F4/80 on the gated population described in A. (C and D) Dermal, lung, liver, pancreatic islets, and kidney cell suspen-
sions were isolated from langerin/EGFP, CX3CR1/EGFP, and WT C57BL/6 mice. (C) Dot plot shows the expression of CD103 versus CD11b (right) on gated non-
lymphoid tissue DAPICD45+CD11c+I-A+ DCs (left). For dermal DCs analysis, DCs were also gated on EPCAM to exclude LCs. (D) Histograms show overlays of 
cell surface marker expression on CD103+ (red) and CD11b+ (blue) DC subsets. These results are representative of three independent experiments (n = 2–3).JEM VOL. 206, December 21, 2009 
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cDCs and are derived from pre-cDCs, whereas tissue CD11b+ 
cDCs are heterogenous.
RESULTS
Two phenotypically distinct nonlymphoid tissue cDC subsets
Langerin, which is highly expressed on the surface of epider-
mal LCs in mice and humans, was initially thought to be a 
specific marker for LCs in the skin (Merad et al., 2008). 
However, langerin is also expressed by a population of der-
mal cDCs, which migrates to the LN (Bursch et al., 2007; 
Ginhoux et al., 2007; Poulin et al., 2007), as well as by a subset 
of cDCs in the lungs (Sung et al., 2006). As shown in Fig. 1,   
steady state (Fogg et al., 2006). Nevertheless, cultured mono-
cytes can develop many of the phenotypic features of cDCs, 
including expression of CD11c and MHC class II (Banchereau 
et al., 2000), and monocytes can repopulate the Langerhans 
cell (LC) compartment in an inflamed epidermis (Ginhoux   
et al., 2006) and give rise to intestinal CX3CR1+ cDCs in the 
steady state (Bogunovic et al., 2009).
In this paper, we explore the mechanisms that control 
cDC homeostasis in nonlymphoid tissues in the steady state. 
We find that two phenotypically and developmentally dis-
tinct cDC populations coexist in most nonlymphoid tissues. 
Tissue CD103+ cDCs are related to lymphoid organ CD8+ 
Figure 2.  Cytokine receptor expression profile among CD103+ and CD11b+ tissue DC subsets. (A and B) DC subsets were sorted from the lung, 
liver, and spleen of C57BL/6 mice and RNA expression was measured by quantitative RT-PCR. Bar graphs present the relative expression of Flt3 (A) and 
MCSF-R (B) in lung and liver CD103+ (white) and CD11b+ (black) DCs and spleen CD8+ (white) and CD8CD11b+ (black) DCs. One representative experiment 
of three independent experiments is shown. (C and D) Dermal, lung, kidney, liver, and spleen cell suspensions were isolated from WT C57BL/6 and MCSF-
R/EGFP mice and analyzed by flow cytometry. (C) Histograms show Flt3 cell surface expression (blue) or isotype antibody control (red) on gated CD103+ 
versus CD11b+ DC subsets in the dermis, lung, kidney, and liver and CD8+ versus CD8CD11b+ DCs in the spleen. (D) Histograms show MCSF-R/EGFP ex-
pression (blue) or WT C57BL/6 control (red) on gated DC subsets in the same tissue. These results are representative of three independent experiments.3118 Origin and development of CD103+ DCs | Ginhoux et al.
Figure 3.  The development of tissue CD103+ DCs is dependent on Flt3 and Flt3L. (A–C) Nonlymphoid tissue DCs isolated from WT, Flt3 KO  
(A and B), and Flt3L KO (C) C57BL/6 mice were analyzed by flow cytometry. (A) Dot plots show CD103 and CD11b expression among gated 
DAPICD45+CD11c+I-A+ DCs in WT (left) and Flt3 KO mice (right). (B) Bar graphs show the absolute numbers of CD103+ and CD11b+ DC subsets among 
tissue DCs in WT (black) versus Flt3 KO (white) versus Flt3L (gray) mice. Bars represent data from six pooled experiments (n = 3–4). Error bars represent JEM VOL. 206, December 21, 2009 
Article
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the mean ± SEM (n = 3). (C) Lethally irradiated CD45.1+ recipient mice were reconstituted with 50% CD45.1+ WT and 50% CD45.2+ WT mixed BM or with 
50% CD45.1+ WT and 50% CD45.2+ Flt3 KO mixed BM and analyzed 2–3 mo after. Bar graphs show the relative contribution of Flt3 KO CD45.2+CD103+ 
DCs (white) among total CD103+ DCs and the relative contribution of Flt3 KO CD45.2+CD11b+ DCs (black) among total CD11b+ DCs. Spleen CD8+ (light 
gray) and CD11b+ DC (black) subsets are also shown. Dark gray bars represent the relative number of Flt3 KO CD45.2+ blood granulocyte chimerism. Data 
shown represent two pooled experiments (n = 3). Error bars represent the means ± SEM. P-values indicate the results of a Student’s t test performed 
between the indicated groups.
 
dermal cDCs can be segregated into three populations that 
differentially express langerin and CD11b. One population 
expresses  langerin,  CD103  (Cepek  et  al.,  1994),  and  low   
levels  of  CD11b  but  lacks  several  monocyte/macrophage 
markers including F4/80 (Austyn and Gordon, 1981), SIRP-  
(van Beek et al., 2005), and CX3CR1 (Jung et al., 2000; 
CD103+ DC; Fig.1, A and B). The other DC subset lacks 
CD103 but expresses high levels of CD11b, CX3CR1, 
F4/80, and SIRP- (CD11b+ DC; Fig.1, A and B). In addi-
tion, the dermis contains migratory LCs, which uniquely   
express epithelial cell adhesion molecule (EpCAM; Nagao   
et al., 2009; Fig. 1, A and B).
To determine whether similar cDC subsets also exist in 
nonlymphoid tissues other than the skin, we examined the 
phenotype of CD11c+MHCII+ cells in the lung, liver, pan-
creatic islets, and kidney. Like in the skin, cDCs in these tis-
sues segregate into two major populations, which we refer to 
as CD103+ DCs (CD103+CD11bloCX3CR1F4/80SIRP-
)  and  CD11b+  DCs  (CD103CD11bhiCX3CR1+F4/
80+SIRP-+; Fig. 1, A–D). The level of langerin expression 
on CD103+ cDCs varies among tissues and is absent in 
CD103+ cDCs in the pancreatic islets (Fig. 1, A–D). We 
conclude that two major subsets of cDCs exist in most mouse 
tissues. We have reported that two DC subsets, identified as 
CD103+ and CD103 cDCs, also exist in mouse lamina pro-
pria (Bogunovic et al., 2009). We recently showed that in 
contrast to most other nonlymphoid tissue, lamina propria   
CD103+ cDCs also express CD11b, F4/80, and SIRP-  
(Fig. S1, A and B; Bogunovic et al., 2009). Intestinal cDCs 
also include a population of CD103+CD11bCD8+ cDCs 
that accumulate in Peyer’s patches (Bogunovic et al., 2009).
Differential expression of fms-like tyrosine kinase 3 (Flt3) 
and the MCSF receptor (MCSF-R)
Expression of the receptor Flt3 is required for the devel-
opment  and  maintenance  of  cDCs  in  lymphoid  organs 
(Waskow et al., 2008). In contrast, MCSF-R is required for 
LCs to develop (Ginhoux et al., 2006) but is dispensable for 
the development of spleen cDCs (Witmer-Pack et al., 1993; 
Ginhoux et al., 2006). This differential cytokine requirement 
may in part reflect the distinct developmental origin of these 
two cell types. Therefore, we measured the expression of 
these two receptors by the different cDC subsets in nonlym-
phoid tissues. Flt3 messenger RNA (mRNA) and protein 
were expressed on both cDC subsets but at higher levels on 
CD103+ cDCs than CD11b+ cDCs in all tissues analyzed in-
cluding the dermis, lung, kidney, and liver (Fig. 2, A and C). 
MCSF-R expression was measured using transgenic mice   
expressing GFP under the control of the MCSF-R promoter 
(Burnett et al., 2004) and confirmed by quantitative PCR. 
Although we did not detect MCSF-R protein expression by 
flow cytometry on cDCs and macrophages, this is likely to be 
a consequence of antigen degradation caused by the long   
tissue digestion process. In contrast to Flt3, MCSF-R was 
expressed at higher levels on CD11b+ cDCs compared with 
CD103+ cDCs in all tissues analyzed (Fig. 2, B and D). Simi-
lar differences were found among spleen CD8 and CD8+ 
cDCs, respectively, suggesting that these cells might be   
developmentally related (Fig. 2, A–D).
Flt3 is required for nonlymphoid tissue cDC homeostasis
Although Flt3 and its ligand (Flt3L) are both essential for nor-
mal lymphoid organ DC development, the effects of Flt3L 
deletion are more pronounced, possibly as a result of the   
existence of a partially redundant receptor (Waskow et al., 
2008). To examine the role of Flt3 in the development   
of  nonlymphoid  tissue  cDCs,  we  measured  CD103+  and 
CD11b+ tissue cDCs in mice that lack Flt3 or Flt3L (Fig. 3, 
A–C). The relative and absolute numbers of CD103+ cDCs 
were strongly reduced in mice that lack Flt3 or its ligand   
in all tissues analyzed including the dermis, lung, liver, and 
kidney (Fig. 3, B and C). CD11b+ cDCs were also strongly 
reduced  in  Flt3L-deficient  mice  (Fig.  3  C),  whereas  Flt3   
deletion had little demonstrable effect (Fig. 3 C). In contrast, 
LCs do not express Flt3 and are unaffected in Flt3- or Flt3L-
deficient mice (Fig. S2), whereas they were absent in mice 
that lack MCSF-R (Ginhoux et al., 2006), which is consis-
tent with a distinct developmental origin for this cell type. 
These results are consistent with previous data showing that 
lung  cDCs  are  strongly  reduced  in  Flt3L-deficient  mice, 
whereas tracheal cDCs are spared in these mice (Walzer et al., 
2005). It seems likely that tracheal cDCs are closely related to 
epidermal LCs and therefore do not express Flt3.
To confirm the role of Flt3 in nonlymphoid tissue cDC 
development, we produced mixed BM chimeras in CD45.1+ 
recipients reconstituted with a mixture of CD45.2+ Flt3/ 
and CD45.1+ WT (50:50%) or control BM cells (Fig. S3 A 
and Fig. 3 D). As expected, Flt3/ BM progenitors were less 
efficient than their WT counterparts in giving rise to all tissue 
DC subsets. However, the effect was far more pronounced 
on CD103+ than CD11b+ cDCs (Fig. 3 D).
MCSF-R is not required for the development of CD103+ cDCs
To determine whether MCSF-R mRNA expression corre-
lates with a requirement for this cytokine for cDC develop-
ment,  we  examined  whether  the  absence  of  MCSF-R 
differentially affects the development of nonlymphoid tissue 
cDC populations. MCSF-R/ mice have several defects, 3120 Origin and development of CD103+ DCs | Ginhoux et al.
Figure 4.  MCSF-R is required for normal development of some nonlymphoid tissue CD11b+ DCs. (A) Dot plots show CD103 and CD11b expres-
sion among tissue CD45+CD11c+I-A+ DCs in MCSF-R KO (right) or control littermate (left) mice. (B) Bar graphs show the relative numbers of CD103+ and  
CD11b+ DC subsets among tissue DCs in control littermates (black) versus MCSF-R KO mice (white). Bars represent data from three pooled experiments  
(n = 2–3). Error bars represent the mean ± SEM. (C) Lethally irradiated CD45.1+ recipient mice were reconstituted with 5% CD45.1+ WT and 95% CD45.2+ 
WT fetal liver or 5% CD45.1+ WT and 95% CD45.2+ MCSF-R KO fetal liver. Bar graphs show the relative contribution of MCSF-R KO CD45.2+CD103+ DCs  
(white) among total CD103+ DCs and the relative contribution of MCSF-R KO CD45.2+CD11b+ DCs (black) among total CD11b+ DCs. Spleen CD8+ (light 
gray) and CD11b+ DC (black) subsets are also shown. Dark gray bars represent the percentage of MCSF-R KO CD45.2+ blood granulocytes chimerism.  
Data shown represent three pooled experiments (n = 3). Error bars represent the means ± SEM. P-values indicate the results of a Student’s t test  
performed between the indicated groups.JEM VOL. 206, December 21, 2009 
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including severe osteopetrosis and tissue trophic defects, that 
may indirectly affect tissue cDC development (Dai et al., 
2002). Nevertheless, we were able to measure CD103+ and 
CD11b+ cDCs in mice that lack MCSF-R. Consistent with 
the higher MCSF-R expression on CD11b+ cDCs (Fig. 2, B 
and D), lack of MCSF-R led to a developmental bias against 
CD11b+ cDCs. CD11b+ cDCs were partially reduced in the 
dermis, lung, and kidney but not in the liver, which is con-
sistent with the moderate role of MCSF-R on liver macro-
phages (Dai et al., 2002; Fig. 4, A and B). In contrast, tissue 
CD103+ cDCs developed normally and remained unaffected 
in MCSF-R/ mice (Fig. 4, A and B).
To determine whether the role of MCSF-R in CD11b+ 
cDC development is cell intrinsic, we produced mixed BM 
chimeras  by  reconstituting  CD45.1+  mice  with  CD45.2+ 
MCSF-R/ fetal liver cells and CD45.1+ WT BM cells 
(95:5%) or control littermate fetal liver cells to favor the en-
graftment of CD45.2+ progenitors, which is compromised in 
the absence of MCSF-R (Fig. 4 C). Consistent with the ob-
servations in MCSF-R KO mice, MCSF-R/ progenitors 
were less efficient than controls in producing CD11b+ cDCs 
in the dermis, lung, and kidney, whereas CD11b+ cDCs devel-
oped normally in the liver in the same mice (Fig. S3 B and 
Fig. 4 C). In contrast, MCSF-R/ progenitors were as efficient 
as controls in giving rise to tissue CD103+ cDCs (Fig. 4 C). 
We conclude that MCSF-R plays a role in the development 
of CD11b+ cDCs in the dermis, lung, and kidney but not the 
liver. Furthermore, it is entirely dispensable for the differen-
tiation of CD103+ DCs in these same tissues.
Nonlymphoid tissue CD103+ DCs share a similar 
developmental program than CD8+ lymphoid organ DCs
The cell surface phenotype of nonlymphoid tissue CD103+ 
cDCs closely resembles that of lymphoid tissue CD8+ cDCs. 
The transcription factor Batf3 is required for CD8+ cDCs   
in the spleen and dermal CD103+ cDCs but not for other   
cDC populations in those organs (Hildner et al., 2008). Both 
CD103+ and CD8+ cDCs excel in cross-presentation of cell-
associated antigens (Bedoui et al., 2009), which suggest that 
these two subsets are closely related. Two other molecules 
have also been shown to control the development of spleen 
CD8+ cDCs, the inhibitor of DNA protein 2 (Id2; Hacker   
et al., 2003) and the IFN regulatory protein 8 (IRF8; Aliberti 
et al., 2003; Tailor et al., 2008).
Both  Id2  and  IRF8  are  expressed  at  higher  levels  on 
CD103+ cDCs compared with CD11b+ cDCs in nonlym-
phoid tissues (Fig. 5 A). Consistent with differential expres-
sion of Id2, its absence blocked the development of CD103+ 
but only had a minor effect on CD11b+ cDCs in the dermis, 
lung, liver, and kidney (Fig. 5, B and C). To determine 
whether the effect of Id2 was cell autonomous, we produced 
mixed BM chimeras. In chimeric mice, Id2/ BM failed to 
differentiate  into  CD103+  cDCs  but  produced  CD11b+ 
cDCs (Fig. S3C and Fig. 5 D). Similar to Id2, absence of 
IRF8 is critical for the development of CD103+ cDCs but   
is dispensable for the development of CD11b+ cDCs (Fig. 5,   
B and C). Id2 and IRF8 were also required for the develop-
ment of Peyer’s patch CD103+CD11bCD8+ cDCs but 
were dispensable for the development of lamina propria 
CD103+CD11b+ cDC (Fig. S1, C–F). Thus, in addition to 
controlling the development of lymphoid organ CD8+ cDCs, 
Id2 and IRF8 are also required for the differentiation of non-
lymphoid CD103+ cDCs but not lamina propria CD103+ 
cDCs or tissue CD11b+ cDCs.
Turnover of nonlymphoid tissue DCs
In the spleen and LNs, cDCs are dividing cells that live for 
10–14 d (Liu et al., 2007). To determine whether nonlym-
phoid tissue cDCs are also dividing, we measured the cells’ 
BrdU uptake and cell cycle distribution in the dermis, lung, 
liver, and kidney. 12 h after BrdU injection, 5–10% of the 
cDCs in the dermis and lung, and 10–20% of the cDCs in the 
liver and kidney were labeled with BrdU (Fig. 6 A). In all tis-
sues analyzed, the relative numbers of BrdU-labeled CD103+ 
cDCs and CD11b+ cDCs were similar, except in the kidney 
where the CD11b+ cDC subset was labeled to a lower level 
(Fig. 6 A). These results were confirmed by cell cycle analysis 
(Fig. 6 B). We conclude that both major cDC subsets in tis-
sues are dividing in the steady state.
To examine the kinetics of cDC turnover in nonlym-
phoid tissues, we established parabiosis between mice ex-
pressing different CD45 alleles (Fig. 6 C). After 2 mo, the 
level of chimerism was 20% for CD103+ cDCs and 30% for 
CD11b+ cDCs, which is similar to the levels for CD8+ and 
CD8 cDCs in the spleen, respectively (Fig. 6 C; Liu et al., 
2009). Chimerism in parabionts is a function of DC turnover 
in tissue, their rate of replacement by blood precursors, and 
the half-life of the precursors in the blood (Liu et al., 2007). 
To determine the rate of replacement of lymphoid tissue 
cDCs by blood precursors, we separated the parabionts after 
2 mo and measured the decay of parabiont-derived cDCs   
in the lung, liver, kidney, and spleen. Parabiont-derived 
CD11b+ and CD103+ cDCs were lost in the 14 d after sepa-
ration in all tissues analyzed (half-life 7 d; Fig. 6 C), except in 
the lung. Lung cDCs had a much longer half-life than cDCs 
in other tissues (Fig. 6 C). In addition, lung CD103+ cDCs 
had a much longer half-life than CD11b+ cDCs in the same 
tissue. 100% of the lung CD11b+ DCs was lost in 30 d after 
separation (half-life 15 d), whereas only 50% of parabiont-
derived lung CD103+ cDCs was lost at that time (half-life 30 d; 
Fig. 6 C). We conclude that cDCs in nonlymphoid tissues 
undergo a limited number of divisions and must be continu-
ally replaced by blood-borne precursors.
Pre-DCs give rise to nonlymphoid tissue CD103+ cDCs
Despite  their  phenotypic  and  functional  differences,  both 
major subsets of cDCs in the spleen and LNs arise from a 
common progenitor, the pre-cDC, which is found in the 
BM, blood, and lymphoid organs (Liu et al., 2009). Little is 
known about the origin of cDCs in nonlymphoid tissues. 
However, several studies suggests that monocytes give rise   
to cDCs in nonlymphoid tissues (Geissmann et al., 2003;   3122 Origin and development of CD103+ DCs | Ginhoux et al.
Figure 5.  The development of CD103+ DCs in tissues is also dependent on Id2 and IRF8. (A) Lung and liver CD103+ and CD11b+ DC subsets and 
spleen CD8+ and CD8CD11b+ DCs were isolated from C57BL/6 mice and mRNA expression of Id2 and IRF8 was measured by quantitative RT-PCR. Bar 
graphs present the relative expression of Id2 (left) and IRF8 (right). One representative experiment of two independent experiments is shown.  
(B and C) Nonlymphoid tissue DCs isolated from WT, Id2 KO, and IRF8 (BXH2) C57BL/6 mice were analyzed by flow cytometry. (B) Dot plots show CD103 JEM VOL. 206, December 21, 2009 
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and CD11b expression among gated DAPICD45+CD11c+I-A+ DCs in WT (left), Id2 KO mice (middle), and IRF8 (BXH2; right). (C) Bar graphs show the abso-
lute numbers of CD103+ and CD11b+ DC subsets among tissue DCs in WT (black), Id2 KO (white), and IRF8 (BXH2; gray) mice. Bars represent data from 
two pooled experiments (n = 2–3). Error bars represent the mean ± SEM. (D) Lethally irradiated CD45.1+ recipient mice were reconstituted with 50% 
CD45.1+ WT and 50% CD45.2+ WT mixed BM or with 50% CD45.1+ WT and 50% CD45.2+ Id2 KO mixed BM and analyzed 2–3 mo after. Bar graphs show 
the relative contribution of Id2 KO CD45.2+CD103+ DCs (white) among total CD103+ DCs and the relative contribution of Id2 KO CD45.2+CD11b+ DCs 
(black) among total CD11b+ DCs. Spleen CD8+ (light gray) and CD11b+ DC (black) subsets are also shown. Dark gray bars represent the percentage of Id2 
KO CD45.2+ blood granulocytes chimerism. Data shown represent two pooled experiments (n = 3). Error bars represent means ± SEM. P-values indicate 
the results of a Student’s t test performed between the indicated groups.
 
Yrlid et al., 2006; Varol et al., 2007; Jakubzick et al., 2008). 
To determine whether pre-cDCs might also give rise to non-
lymphoid tissue cDCs, we looked for these cells in the lung, 
liver, and kidney (Fig. 7 A). We were unable to assess the 
presence  of  pre-cDCs  in  the  dermis  because  of  the  low   
recovery yield of dermal cells. Pre-cDCs were present in each 
of  these  tissues  and  their  accumulation  in  nonlymphoid   
tissues was strongly dependent on Flt3L (Fig. 7, A and B).   
In the absence of Flt3L, we found fewer pre-cDCs in all 
nonlymphoid organs, and this decrease in pre-cDC was also 
directly proportional to the decrease in both CD103+ and 
CD11b+ cDC populations (Fig. 7 C and Fig. 3 C). Parabiosis 
experiments established that pre-cDC chimerism was similar 
in the blood, liver, lung, kidney, and spleen and proportional 
to both CD103+ and CD11b+ cDC chimerism in these   
organs (Fig. 7 C). Therefore, in addition to migrating to lym-
phoid organs, pre-cDCs also migrate from the BM through 
the blood to nonlymphoid tissues.
To determine the relative contribution of DC progeni-
tors and monocytes to the development of nonlymphoid   
tissue cDCs, we injected pre-cDCs, monocytes, CDPs, and 
MDPs from C57BL/6 mice into untreated congenic recipi-
ent mice. We then measured the presence of donor-derived 
cDCs in nonlymphoid tissues 1 wk after adoptive transfer. 
Donor-derived cDCs were nearly undetectable in the lung 
and dermis, which limited our analysis to the liver and kid-
ney (Fig. 8 and not depicted). As expected, MDPs, which 
produce  monocytes  and  DCs,  gave  rise  to  CD103+  and 
CD11b+ cDCs (Fig. 8, A and B). CDPs, which produce 
DCs  but  not  monocytes  (Naik  et  al.,  2007;  Onai  et  al., 
2007b), also gave rise to both CD103+ and CD11b+ cDCs 
(Fig. 8, A and B). The ratio of CD103+ to CD11b+ cDCs 
derived from CDPs was comparable to that obtained from 
MDPs (Fig. 8, A and B), which suggests that despite losing 
the ability to produce monocytes, CDP remained able to 
give rise to CD103+ and CD11b+ cDCs. Consistent with 
this idea, pre-DCs, which are restricted to producing cDCs, 
gave rise to both CD103+ and CD11b+ cDCs in the liver 
and kidney (Fig. 8, A and B). Monocytes were much less ef-
ficient in giving rise to cDCs in this assay. We were unable 
to detect monocyte-derived cDCs in four experiments when 
106 monocytes were transferred but found small numbers of 
CD11b+ DCs and no CD103+ cDCs when we transferred   
3 × 106 monocytes (Fig. 8 C). We conclude that nonlym-
phoid tissue CD103+ cDCs derive from pre-cDCs, whereas 
CD11b+ cDCs are heterogenous.
DISCUSSION
Our results show that two types of cDCs are present in most 
nonlymphoid tissues, with the exception of the lamina pro-
pria, and that different developmental programs regulate 
these cells. CD103+ cDCs resemble lymphoid tissue CD8+ 
cDCs in that they are critically dependent on Flt3L, Id2, and 
IRF8 and they are derived from pre-cDCs. In contrast, 
CD11b+ cDCs are dependent on both Flt3L and MCSF-R 
but are independent of Id2 and IRF8.
Flt3 and MCSF-R are differentially expressed by DCs 
and monocyte/macrophages (Pixley and Stanley, 2004; Onai 
et al., 2007a). As could be expected from this phenotypic dif-
ference, cDC development in lymphoid tissues is dependent 
on Flt3 and Flt3L, whereas monocyte/macrophage develop-
ment depends on MCSF-R (Pixley and Stanley, 2004; Onai 
et al., 2007a). CD103+ cDCs express low levels of MCSF-R, 
as shown in MCSF-R reporter mice, they do not express 
macrophages markers, and they do not require MCSF-R for 
their development. Like CD8+ cDCs in lymphoid organs, 
CD103+ cDCs in tissues originate from pre-cDCs, not from 
monocytes, and are critically dependent on Flt3L.
Nonlymphoid tissue CD11b+ cDCs share several cell sur-
face markers with macrophages and appear to be more closely 
related to monocyte/macrophages than to cDCs. They express 
F4/80, SIRP-, CD11b, and CX3CR1. Consistent with these 
features, CD11b+ cDCs in the skin, lung, and kidney, includ-
ing epidermal LCs (Ginhoux et al., 2006), are partially MCSF-
R dependent. MCSF-R expression is gradually lost by cDCs as 
they develop from MDPs, CDPs, and pre-cDCs, but MCSF-
R continues to be expressed in nonlymphoid tissue CD11b+ 
cDCs to a greater extent than in CD103+ cDCs. Despite these 
phenotypic differences, and their dependence on MCSF-R, 
some nonlymphoid tissue CD11b+ cDCs can be reconstituted 
by pre-DCs. Finally, both subsets of nonlymphoid tissue cDCs 
are also depend on Flt3L for their development.
Flt3 is expressed throughout the DC lineage (Naik et al., 
2007; Onai et al., 2007b; Waskow et al., 2008; Liu et al., 
2009)  but  it  is  strongly  reduced  in  nonlymphoid  tissue 
CD11b+ cDCs compared with CD103+ cDCs. Consistent 
with this difference in gene expression, the development of 
CD103+ cDCs is more strongly affected in Flt3- and Flt3L-
deficient mice compared with CD11b+ cDCs, as was re-
cently suggested by Kingston et al. (2009). The defect in 
both  nonlymphoid  tissue  cDCs  in  Flt3L-deficient  mice 
likely reflects the role of this cytokine in the commitment   
of  early  hematopoietic  progenitors  to  the  DC  lineage   3124 Origin and development of CD103+ DCs | Ginhoux et al.
Id2 is a dominant-negative inhibitor of E2A, a basic helix-
loop-helix transcription factor that plays a key role in hemato-
poietic cell differentiation (Engel et al., 2001). The balance of 
Id2 and E2A is thought to influence lineage fate decision in 
hematopoiesis. For example, targeted mutation of Id2 inhibits 
NK cell development (Yokota et al., 1999), whereas targeted 
(Christensen and Weissman, 2001; Karsunky et al., 2003; 
Naik et al., 2007; Onai et al., 2007b; Liu et al., 2009), 
whereas the more pronounced reduction of CD103+ cDCs 
in these mice may be a result of the additional role of Flt3L 
in the survival or proliferation of CD103+ cDCs in nonlym-
phoid tissues (Waskow et al., 2008).
Figure 6.  Turnover of nonlymphoid tissue DC subsets. (A and B) BrdU incorporation and proliferation index of tissue DC subsets were measured  
by flow cytometry. Dermal, lung, liver, kidney, and spleen cell suspensions were isolated from WT C57BL/6 mice. (A) Bar graphs show the relative numbers  
of BrdU+ cells among CD103+ and CD11b+ DC subsets in nonlymphoid tissues and among CD8+ and CD8CD11b+ spleen DCs after a 2-h (white) or a 12-h 
(black) BrdU pulse. Bars represent data from two pooled experiments (n = 3). Error bars represent the mean ± SEM. (B) Bar graph shows the percentage of 
proliferating cells (% S/G2/M) measured by DNA content among CD103+ (white) and CD11b+ (black) DC subsets in nonlymphoid tissues and among CD8+ 
(grey) and CD8CD11b+ (black) spleen DCs. Bars represent data from three pooled experiments (n = 3). Error bars represent the mean ± SEM. (C) Tissue  
DC mixing in parabiotic mice. CD45.2 and CD45.1 C57BL/6 mice were surgically joined for 55 d before being separated. Graphs show the percentage of 
parabiont-derived DCs among each DC subset in the lung, liver, kidney, and spleen at different times after parabiont separation. Bars represent two  
separate parabionts at each time point. Error bars represent the mean ± SEM.JEM VOL. 206, December 21, 2009 
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Figure 7.  Pre-DCs are present in nonlymphoid tissues. (A) Dot plots show the relative numbers of CD45+MHCII+CD11cFlt3hiSIRP- pre-DCs 
among hematopoietic cells in the lung, kidney, liver, and spleen. (B) Bar graph shows the relative numbers of pre-DCs in indicated organs of Flt3L+/+  
(WT, white) and Flt3L/ (black) mice. One representative experiment of three (A) and two (B) independent experiments is shown (n = 2). (C) CD45.2 and 
CD45.1 C57BL/6 mice were surgically joined for 55 d. Graphs show the percentage of parabiont-derived T cells, B cells, and pre-DCs in the blood and  
the percentage of parabiont-derived pre-DCs in the lung, kidney, liver, and spleen 55 d after parabiosis was established. The bar graphs summarize two  
independent experiments with more than three mice in total. Error bars represent the mean ± SEM.3126 Origin and development of CD103+ DCs | Ginhoux et al.
Figure 8.  Tissue DCs arise from pre-DCs in vivo. (A and B) MDPs, CDPs, and pre-DCs were purified from the BM of CD45.1+ mice, as described in  
the Material and methods, and adoptively transferred into unconditioned CD45.2+ congenic host. (A) Dot plots show the percentage of CD45.1+ donor- 
derived DCs among total kidney and liver DAPICD11c+MHCII+ DCs in mice injected with MDP, CDP, and pre-DCs. Host corresponds to the endogenous 
(CD45.2+) DC population. (B) Bar graph shows the mean absolute numbers of CD45.1+ donor-derived MHCII+CD11c+ DCs normalized to a 105 cells input  
of MDPs (black), CDPs (gray), and pre-DCs (white). Bars represent data from four pooled experiments (n = 1–2). Error bars represent the means ± SEM.  
(C) Monocytes were purified from the BM of CD45.2+ mice, as described in the Material and methods, and adoptively transferred into unconditioned CD45.1+ 
congenic host. Dot plot show the percentage of donor CD45.2+ monocyte-derived DCs among total kidney and liver DAPICD11c+MHCII+ DCs in mice 
injected with 1.2 × 106 or 3 × 106 monocytes. Host corresponds to the endogenous (CD45.1+) DC population. Control represents noninjected mice.
mutation of E2A inhibits B and T cell development (Engel   
et al., 2001). Id2/ mice show normal tissue macrophages in 
all tissues analyzed (unpublished data), whereas they specifically 
lack CD8+, but not CD8, cDCs in the spleen (Hacker et al., 
2003) and CD103+ cDCs in nonlymphoid tissues. IRF-8/IFN 
consensus sequence-binding protein (ICSBP) is an IFN-–
  inducible transcription factor of the IRF family that controls 
myeloid cell differentiation (Gabriele and Ozato, 2007). BXH2 
mice that carry a spontaneous point mutation in ICSBP1/ 
IRF-8 (IRF8C294; Turcotte et al., 2005) lack CD8+ cDCs but not   
CD8 cDCs or plasmacytoid DCs in lymphoid organs (Tailor   
et al., 2008). In addition to Id2, IRF8 also plays a key role in the 
development of nonlymphoid tissue CD103+ but not CD11b+ 
cDCs. Importantly, Id2 and IRF8 also controlled the differenti-JEM VOL. 206, December 21, 2009 
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differentiation and play a nonredundant and essential role in 
initiating CD8+ T cell responses.
MATERIALS AND METHODS
Mice.  C57BL/6  (CD45.2+)  mice,  congenic  C57BL/6  CD45.1+  mice, 
MCSF-R/GFP C57BL/6 mice (macrophage fas-induced apoptosis; Burnett 
et al., 2004) and BXH2 C57BL/6J C3H/HeJ mice that carry a spontaneous 
point mutation (R294C) in the transcriptional regulator Icsbp1/IRF8   
(Icsbp1C294; Turcotte et al., 2005) were purchased from The Jackson Labora-
tory. Flt3L/ mice (McKenna et al., 2000) were purchased from Taconic. 
CX3CR1/GFP C57BL/6 mice (Jung et al., 2000) were provided by D.   
Littman (Skirball Institute, New York, NY), Langerin/GFP C57BL/6 and 
Langerin/DTR-GFP C57BL/6 mice (Kissenpfennig et al., 2005) were pro-
vided by B. Malissen (Centre d’Immunologie Marseille-Luminy, Marseille, 
France), and Flt3/ C57BL/6 mice (Mackarehtschian et al., 1995) were 
provided by I. Lemischka (Mount Sinai School of Medicine, New York, 
NY). Id2/ C57BL/6 (Yokota et al., 1999) were provided by Y. Yokota 
(University of Fukui, Fukui, Japan). MCSF-R/ FVB/NJ mice (Dai et al., 
2002) were produced as previously described and bred in our animal facility. 
All mice were analyzed between 8 and 12 wk of age, with the exception of 
MCSF-R/ mice which were analyzed at 3 wk of age. All animal protocols 
were approved by the Institutional Committee on Animal Welfare of the 
Mount Sinai Medical School (New York, NY).
In vivo reconstitution assays. In Flt3/ and Id2/ mixed BM chimeras, 
CD45.1+ C57BL/6 mice were lethally irradiated (2× 600 rad, 3 h apart using 
a Cesium source) and reconstituted with a 1:1 mixture of CD45.1+ WT BM 
and CD45.2+ BM isolated from WT or mutant mice. In MCSF-R/  
chimera, fetal liver cells were used as a source of MCSF-R/ hematopoietic 
precursor cells because C57BL/6 MCSF-R/ mice are embryonically lethal 
(Dai et al., 2002). Lethally irradiated CD45.1+ C57BL/6 mice received a 
mixture of MCSF-R/ CD45.2+ fetal liver cells and syngeneic WT CD45.1+ 
BM (95: 5%) or MCSF-R+/+ CD45.2+ control littermates fetal liver cells and 
syngeneic WT CD45.1+ BM (95:5%). In all transplanted mice, engraftment 
was assessed by measuring the percentage of donor cells among blood Ly6C/
G+ MCSF-R/ granulocytes 3–4 wk after transplantation.
Cell suspensions preparation. Skin cell suspensions were isolated as pre-
viously described (Ginhoux et al., 2007) and analyzed by flow cytometry. In 
brief, mouse ears were split in two (dorsal and ventral) parts and incubated 
for 60 min in HBSS containing 2.4 mg/ml Dispase (working activity of   
1.7 U/mg; Invitrogen) to allow for separation of dermal and epidermal sheets. 
Epidermal  and  dermal  sheets  were  then  cut  into  small  pieces,  incubated   
for 2 h in HBSS containing 10% FBS and 0.2 mg/ml collagenase type IV 
(working activity of 770 U/mg; Sigma-Aldrich), and then passed trough a 
19G syringe to obtain homogeneous cell suspension. Lung, liver, kidney, 
and pancreatic islets (isolated as previously described [Zhang et al., 2003]) 
were isolated, homogenized, incubated for 1 h in 10% FBS HBSS containing 
0.2 mg/ml collagenase type IV (working activity of 770 U/mg), and passed 
trough a 19G syringe to obtain homogeneous cell suspension. Cell suspen-
sions were then run either trough a room temperature NycoPrep gradient 
1.077 (Axis-Shield; for lung and kidney) or a room temperature isotonic 
Percoll  density  (GE  Healthcare;  for  liver)  centrifugation  to  enrich  the   
percentage of hematopoietic cells, as per the manufacturer’s instructions. 
Lamina propria cell suspensions were prepared as described by Bogunovic   
et al. (2009). The analysis of hematopoietic cell populations present in tissue 
cell suspensions was assessed by flow cytometry by gating on singlets DAPI 
(Invitrogen) CD45+ cells for extracellular staining or singlets CD45+ cells for 
intracellular langerin staining.
Flow cytometry and cell sorting. Multiparameter analyses of stained cell 
suspensions were performed on an LSR II (BD) and analyzed with FlowJo 
software (Tree Star, Inc.). Fluorochrome- or biotin-conjugated mAbs spe-
cific to mouse B220 (clone RA3-6B2), CD8a (clone 53–6.7), IA/IE (clone 
M5/114.15.2), CD103 (clone 2E7), SIRP- (clone P84), CD117 (clone 2B8),   
ation of CD103+CD11bCD8+ Peyer’s patch cDCs but failed 
to control the differentiation of CD103+CD11b+ lamina pro-
pria cDCs. These results further emphasize the common re-
quirements  for  development  and  homeostasis  of  lymphoid 
CD8+ cDCs and most nonlymphoid organ CD103+ cDCs 
with the exception of lamina propria CD103+ cDCs.
Pre-cDCs develop in the BM and migrate though blood 
to seed lymphoid organs, where they give rise to CD8+  
and CD8 cDCs (Liu et al., 2009). Our results revealed that   
pre-cDCs also migrate to nonlymphoid tissues, where they 
differentiate into CD103+ and CD11b+ cDCs with a devel-
opment bias toward CD103+ cDCs. Both DC types divide in 
situ, but they have a limited number of divisions and their 
half-life in the tissues is variable, ranging from 7 d in the kid-
ney and liver to 30 d in the lung.
Monocytes were unable to differentiate into nonlym-
phoid tissue CD103+ cDCs. However, they can produce 
lamina propria CD103CD11b+ cDCs without contribu-
tion from CDPs or pre-cDCs (Bogunovic et al., 2009). In 
contrast, in the kidney and liver, CDPs and pre-cDCs can 
contribute to the CD11b+ cDC pool. Monocytes only gave 
rise to CD11b+ cDCs at low efficiency in the steady state, 
but we cannot rule out the possibility that poor monocyte 
survival in adoptive transfer is, in part, responsible for this 
effect.  The  development  of  genetic  lineage  tracing  tools 
should resolve this issue. These results are consistent with 
previous studies showing that monocytes fail to give rise   
to lung CD11c+CD11b cells (Landsman et al., 2007; Varol 
et al., 2007) but can produce lung CD11c+CD11b+ cells 
in  the  steady  state.  Although  in  these  studies  lung 
CD11c+CD11b cells were originally called macrophages, 
it is likely that lung CD103+ cDCs were also included in 
this  population.  In  addition,  in  these  studies  (Landsman   
et al., 2007; Varol et al., 2007) monocyte contribution to 
lung cDCs was revealed in mice depleted of cDCs using 
diphtheria toxin. In contrast, we have adoptively transferred 
monocytes only in naive untreated animals and it is possible 
that the poor monocyte contribution to the tissue DC pool 
observed in our study could be enhanced in mice depleted 
of endogenous cDCs.
Although less is known about the physiological function 
of DC subsets in nonlymphoid than lymphoid tissues, CD103+ 
and CD11b+ cDCs appear to be functionally specialized. 
CD103+ cDCs cross-present extracellular antigens to CD8+  
T cells in skin (Bedoui et al., 2009), and in the lung they are   
required for optimal influenza virus responses (GeurtsvanKessel   
et al., 2008). These results are quite remarkable because   
CD103+ cDCs are only a minor fraction of the DCs in the 
dermis and in the lung, suggesting that CD103+ cDCs play a 
unique role in tissue immunity, which is consistent with their 
common origin with CD8+ lymphoid tissue cDCs.
In conclusion, our results identify two distinct popula-
tions  of  DCs  in  nonlymphoid  tissues  that  originate  from   
pre-cDCs. Like CD8+ cDCs in lymphoid tissues, nonlym-
phoid tissue CD103+ DCs, with the exception of lamina   
propria CD103+ cDCs, require Flt3L, Id2, and IRF8 for their 3128 Origin and development of CD103+ DCs | Ginhoux et al.
Statistical analysis. Mann-Whitney and unpaired Student’s t tests (with a 
95% confidence) were performed using Prism 4.0 (GraphPad Software, 
Inc.). All p-values are two-tailed.
Online  Supplemental  material. Fig. S1 shows that lamina propria 
CD103+ DCs are distinct from most nonlymphoid tissue CD103+ DCs. 
Fig.  S2  shows  that  epidermal  LCs  develop  independently  of  Flt3  and   
Flt3L. Fig. S3 shows WT control chimerism for mixed chimera experiments. 
Online supplemental material is available at http://www.jem.org/cgi/ 
content/full/jem.20091756/DC1.
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